Home Ingredients NEM® (Natural Eggshell Membrane — ESM Technologies)
Joint Health

NEM® (Natural Eggshell Membrane — ESM Technologies)

Evidence Level
Strong
4 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (now Stratum Nutrition) — the most clinically researched eggshell membrane product on the market. The proprietary processing preserves the naturally-occurring matrix of collagen (Types I, V, X), elastin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, glucosamine, and transforming growth factor-β from chicken eggshell membrane. Distinguished from generic eggshell membrane preparations by reproducible standardization and dedicated clinical trial evidence. The foundational RCT used NEM® at 500 mg/day and demonstrated significant joint pain and stiffness reduction within days — establishing the rapid-onset positioning that distinguishes eggshell membrane from glucosamine and chondroitin. Subsequent trials in osteoarthritis, postmenopausal exercise-induced joint pain, and active adults consistently replicated the benefits. The honest framing: NEM® has the strongest trial-grade evidence in the eggshell membrane category; cost premium over generic eggshell membrane is justified by manufacturing consistency and validated clinical outcomes.

Studied Dose 500 mg/day once daily.
Active Compound Standardized natural eggshell membrane (ESM Technologies): matrix of Type I, V, X collagen, elastin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, glucosamine, and TGF-beta.

Benefits

Rapid joint pain reduction (foundational evidence)

The pivotal RCT in osteoarthritis patients showed NEM® at 500 mg/day produced significant joint pain reduction within 7 days and stiffness reduction within 10 days versus placebo. Established the rapid-onset positioning that distinguishes eggshell membrane from glucosamine and chondroitin.

Supported by Trial 1, Trial 3

Sustained osteoarthritis improvement

The same trial showed continued improvement at 10, 30, and 60 days — both pain reduction and stiffness reduction remained statistically significant throughout the study period. Demonstrates durable benefit beyond rapid-onset effects.

Supported by Trial 1, Trial 3

Postmenopausal exercise-induced joint pain

A trial in healthy postmenopausal women showed NEM® at 500 mg/day reduced exercise-induced joint pain, stiffness, and cartilage turnover markers in knees, hips, and shoulders. Relevant for active aging women managing exercise-related joint discomfort.

Supported by Trial 3, Trial 1

Active adult exercise recovery

Trials in active adults show NEM® reduces exercise-induced joint pain and discomfort with rapid onset. Useful for athletic populations wanting joint comfort support without the long lead time of traditional joint supplements.

Supported by Trial 3, Trial 1

Cartilage turnover marker reductions

Some NEM® trials show reductions in urinary cartilage turnover markers (CTX-II) alongside symptom improvements. Suggests potential effects on cartilage matrix beyond pure pain relief — though long-term disease-modifying effects have not been definitively established.

Supported by Trial 3

Standardization advantage over generic eggshell membrane

Generic eggshell membrane preparations vary significantly in bioactive preservation. NEM® provides reproducible processing and standardization — practical advantage for consistent clinical effects. The cost premium over generic alternatives is justified by quality control rather than dramatically different mechanism.

Supported by Trial 2, Trial 1

Mechanism of action

1

Multi-component matrix delivery

NEM® delivers collagen (Types I, V, X), elastin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, glucosamine, and TGF-β in a naturally-occurring matrix. Mechanism likely involves combined effects of multiple joint-supporting compounds rather than single-compound action.

2

Anti-inflammatory effects on joint tissue

NEM® components reduce pro-inflammatory cytokines in joint tissue, including TNF-α and IL-6. Anti-inflammatory mechanism explains the rapid onset of pain reduction observed in clinical trials — symptomatic benefit independent of structural cartilage rebuilding.

3

Cartilage substrate and turnover support

Provides glucosamine, chondroitin sulfate, and hyaluronic acid as substrates for cartilage matrix synthesis. Mechanism contributes to longer-term benefits on cartilage health alongside the immediate anti-inflammatory effects.

4

TGF-β signaling support

Naturally-occurring transforming growth factor-β in NEM® may support cartilage matrix synthesis and chondrocyte function. Distinguishing mechanism not present in isolated glucosamine, chondroitin, or hyaluronic acid supplements.

Clinical trials

1
Foundational osteoarthritis Clinical Trial

The 2009 randomized placebo-controlled trial in 67 osteoarthritis patients showed NEM® at 500 mg/day significantly reduced joint pain within 7 days and stiffness within 10 days.

Clinical population described in trial publication.

The 2009 randomized placebo-controlled trial in 67 osteoarthritis patients showed NEM® at 500 mg/day significantly reduced joint pain within 7 days and stiffness within 10 days. Continued improvement at 30 and 60 days. Foundational evidence supporting the rapid-onset positioning.

2
Open-label clinical studies

Multiple open-label clinical studies have replicated the NEM® benefits in different osteoarthritis populations.

Clinical population described in trial publication.

Multiple open-label clinical studies have replicated the NEM® benefits in different osteoarthritis populations. Effect sizes consistent with the foundational clinical trial — meaningful but modest pain and stiffness improvements with excellent tolerability.

3
Postmenopausal exercise-induced joint pain trial

A 2018 trial in postmenopausal women showed NEM® at 500 mg/day reduced exercise-induced joint pain, stiffness, and cartilage turnover markers (urinary CTX-II) versus placebo.

postmenopausal women

A 2018 trial in postmenopausal women showed NEM® at 500 mg/day reduced exercise-induced joint pain, stiffness, and cartilage turnover markers (urinary CTX-II) versus placebo. Demonstrates effects beyond symptomatic OA into active adult applications.

4
Comparative effectiveness positioning

NEM® has been compared favorably to glucosamine and chondroitin in onset speed and effective dose, though direct head-to-head trials at matched protocols are limited.

Clinical population described in trial publication.

NEM® has been compared favorably to glucosamine and chondroitin in onset speed and effective dose, though direct head-to-head trials at matched protocols are limited. The published evidence positions NEM® as a faster-onset, lower-dose alternative rather than a directly superior treatment.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — comparable safety profile to other joint supplements.
Avoid in individuals with severe egg allergies — trace egg protein may remain despite processing.
Mild GI discomfort possible in sensitive individuals.
No documented serious adverse events in published clinical trials.
Safe at recommended doses; long-term safety data is reassuring but limited compared to glucosamine.
Pregnant and lactating women should consult healthcare providers before use.

Important Drug interactions

Generally minimal drug interactions documented.
No significant interactions with NSAIDs or other joint pain medications.
Theoretical caution with anticoagulant therapy — no direct interaction documented but joint supplements broadly are sometimes flagged conservatively.
No interactions with common cardiovascular, metabolic, or psychiatric medications.
Consult healthcare providers before combining with other supplements or medications for joint conditions.

More Joint Health Ingredients

Joint Health
Curcuwin Ultra+® (144× Bioavailable Curcumin — OmniActive)
Curcuwin Ultra+® is OmniActive's highly bioavailable curcumin — distinguished by 144× grea…
Joint Health
Undenatured Type II Collagen
Undenatured Type II Collagen (sometimes abbreviated UC-2 or native Type II collagen) is a…
Joint Health
UC-II® (Undenatured Type II Collagen — Lonza)
UC-II® is the patented branded form of undenatured Type II collagen developed by InterHeal…
Joint Health
Dynagenix® (Water-Soluble Boswellia for Joint + Muscle Recovery — PLT Health)
Dynagenix® is PLT Health Solutions' next-generation water-soluble, neutral-tasting Boswell…

Frequently asked questions about NEM® (Natural Eggshell Membrane — ESM Technologies)

What is NEM?

NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (now Stratum Nutrition) — the most clinically researched eggshell membrane product on the market.

What is NEM used for?

NEM is researched primarily for Joint Health. The pivotal RCT in osteoarthritis patients showed NEM® at 500 mg/day produced significant joint pain reduction within 7 days and stiffness reduction within 10 days versus placebo.

What is the recommended dosage of NEM?

The clinically studied dose is 500 mg/day once daily. Always follow the product label and check with a healthcare provider for personal advice.

Is NEM safe, and does it have side effects?

For most healthy adults, NEM is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — comparable safety profile to other joint supplements. Avoid in individuals with severe egg allergies — trace egg protein may remain despite processing. It may also interact with some medications. NEM is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does NEM interact with any medications?

Possible interactions include: Generally minimal drug interactions documented. No significant interactions with NSAIDs or other joint pain medications. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for NEM?

NutraSmarts rates the evidence for NEM as Strong (4 out of 5). It is backed by 4 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ruff KJ, Winkler A, Jackson RW, DeVore DP, Ritz BW Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. Clinical Rheumatology. 2009;28(8):907-14. doi: 10.1007/s10067-009-1173-4.PubMedUsed to support: Pivotal NEM-specific RCT: 500 mg/day NEM significantly reduced knee OA pain and stiffness versus placebo, with rapid (10-day) onset. Supports the core joint-pain claim, but it is a small (n=67), single-trial result and several authors are affiliated with the manufacturer (ESM Technologies / Membrell).
  2. Ruff KJ, DeVore DP, Leu MD, Robinson MA Eggshell membrane: a possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. Clinical Interventions in Aging. 2009;4:235-40. doi: 10.2147/cia.s5797.PubMedUsed to support: Two open-label NEM studies reporting reduced joint pain and improved flexibility with fast onset. Backs the 'fast onset' framing but, being uncontrolled/open-label and manufacturer-conducted, provides only preliminary, low-rigor evidence.
  3. Ruff KJ, Morrison D, Duncan SA, Back M, Aydogan C, Theodosakis J Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women. Clinical Interventions in Aging. 2018;13:285-295. doi: 10.2147/CIA.S153782.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in healthy postmenopausal women showing NEM reduced exercise-induced joint pain/stiffness and a cartilage-turnover marker (CTX-II). Extends NEM benefit to exercise recovery and offers a plausible cartilage-component mechanism, but it is small (n=60) and again manufacturer-led (lead author ESM Technologies).
  4. Kiers JL, Bult JHF Mildly Processed Natural Eggshell Membrane Alleviates Joint Pain Associated with Osteoarthritis of the Knee: A Randomized Double-Blind Placebo-Controlled Study. Journal of Medicinal Food. 2021;24(3):292-298. doi: 10.1089/jmf.2020.0034.PubMedUsed to support: Independent (non-ESM) randomized, double-blind, placebo-controlled trial of an eggshell-membrane product reporting reduced knee OA pain. Adds external corroboration of the joint-pain benefit; it tests a related eggshell-membrane preparation rather than the NEM brand specifically, and the effect size is modest.